Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) EPS (Weighted Average and Diluted) (2017 - 2026)

Champions Oncology has reported EPS (Weighted Average and Diluted) over the past 14 years, most recently at -$0.02 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) fell 106.45% year-over-year to -$0.02; the TTM value through Jan 2026 reached -$0.16, down 136.36%, while the annual FY2025 figure was $0.33, 161.11% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was -$0.02 at Champions Oncology, down from $0.02 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.31 in Q1 2025 and troughed at -$0.19 in Q2 2023.
  • A 5-year average of -$0.04 and a median of -$0.02 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 12583.1% in 2023 and later skyrocketed 263.16% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.0 in 2022, then plummeted by 12583.1% to -$0.15 in 2023, then soared by 133.33% to $0.05 in 2024, then tumbled by 60.0% to $0.02 in 2025, then crashed by 200.0% to -$0.02 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CSBR at -$0.02 in Q1 2026, $0.02 in Q4 2025, and -$0.03 in Q3 2025.